Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The seventeenth stock on our list is Arcturus Therapeutics Holdings Inc.

TheFly reported on January 22 that Roth Capital initiated coverage of ARCT with a Buy rating and a $20 price target. The firm noted that the company’s two mid-stage programs show clinical activity and have peak sales potential that exceed $1 billion. Roth also highlighted that ARCT shares are trading close to their cash value, effectively pricing in a 0% chance of success for these assets, which makes ARCT potentially one of the most mispriced stocks in rare disease.

Similarly, earlier on January 6, Citigroup lowered its price target for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) from $9 to $7 and maintained a Neutral rating. The firm highlighted opportunities in SMID-cap biotech for 2026, particularly in companies at the commercial or near-commercial stage.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a biotechnology company developing mRNA‑based vaccines and RNA therapeutics using proprietary delivery technologies. Its pipeline targets infectious diseases like COVID‑19 and influenza, as well as rare liver and respiratory disorders.

While we acknowledge the potential of ARCT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.